Ministry of Foreign Affairs of Japan Medical Visa Guarantee Agency No. B-66
Fukuoka Prefecture, Japan Travel service No. 35
Japanese Registration Support Organization No. 19-000303
Japan Medical Equipment Sales and Leasing
Medical Supporter
Accompanied with heart, medical care support in Japan
Immune Cell BAK Therapy
Shiba International Club
What are the characteristics of Cell Therapy BAK?
(1) In "BAK therapy", the cultivated immune cells can recognize normal cells and attack other abnormal cells, that is, cancer cells. Therefore, there is very high efficiency.
(2) Immune cell therapy NK and γδT cells (CD56 positive) are used independently for immune cells "BAK therapy" to suppress killer activity (the ability to attack abnormal cells), when HLA-I (leukocyte antigen) of normal cells is recognized, it is Does not attack normal cells. When faced with cancer cells, as long as there is no HLA-I (leukocyte antigen), immune cells will recognize that the cells are not normal cells and attack them. In addition, NK and βT cells (CD56 positive) attack through NKG2D molecular recognition of MIC A/B molecules expressed in abnormal cells such as cancer cells. This mechanism also does not attack normal cells.
(3) Using a proprietary serum-free medium, the cultured immune cells grow to about 10 billion in an overwhelming manner.
The serum-free ALyS-BAK medium used in the cancer treatment immune cell "BAK therapy" has an excellent immune cell proliferation function compared to other media. Also, since human serum is not used, there is no risk of infection with unknown viruses or mycoplasma.
Differences between BAK therapy and other immune cell therapies
BAK therapy
CTL therapy
CTL therapy and dendritic cell therapy use killer T cells to attack cancer cells, but they cannot attack cancer cells that do not have HLA-I. In contrast, BAK therapy mainly allows the proliferation of positive CD56 cells, which can attack cancer cells that cannot be attacked by CTL therapy and dendritic cell therapy to exert curative effect.
dendritic cell therapy
NK cell therapy
γδT cell therapy
NK cell therapy is the same as γδT cell therapy and BAK therapy, both targeting positive CD56 cell proliferation. The difference is that fewer immune cells are proliferated and only a single cell is cultured. Under the optimal culture technology of BAK therapy, in addition to the number of NK cells and γδT cells, it also includes killer T cells and helper T cells. Therefore, it can attack cancer cells in many ways, and it is expected to have better curative effect.
IAF (Immune Adjusting Factor)
How to use IAF to destroy cancer cells?
Because cancer patients will produce Nagalase to inhibit Gc protein, resulting in the inability to form macrophage growth factor (MAF), since macrophages must be activated by MAF, macrophages will not be able to attack cancer cells in the body to attack. At this time, the immunomodulatory factor (IAF) is provided to the patient through artificial synthesis to activate the macrophages to attack cancer cells.